RAPT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of RAPT Therapeutics, Inc. is Fair to Shareholders

Core Viewpoint - The investigation by Halper Sadeh LLC focuses on the fairness of the sale of RAPT Therapeutics, Inc. to GSK plc at a price of $58.00 per share for RAPT shareholders [1] Group 1: Investigation Details - The investigation examines whether RAPT and its board violated federal securities laws and fiduciary duties by not ensuring the best possible consideration for shareholders [2] - Concerns include whether GSK is underpaying for RAPT and if all material information necessary for shareholders to assess the merger was disclosed [2] Group 2: Potential Actions - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other forms of relief related to the proposed transaction [3] - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [3] Group 3: Firm Background - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]